If all three drugs fail and fail miserably the Alzheimer's community is in trouble. The pharmaceutical companies might give up. They might conclude that Alzheimer's cannot be treated effectively.
By Bob DeMarco
Alzheimer's Reading RoomWe are down to the one inch line on three new drugs, potential treatments, for Alzheimer's disease.
The Phase 3 clinical trials for Bapineuzumab and Solanezumab are scheduled to be released in the next few months, maybe as early as next month. A third drug, Gammagard, could report next year.
Some say if the drugs fail it could be the end of Alzheimer's research as we know it. That major pharmaceutical companies might out of frustration cut back on research spending for Alzheimer's disease.
Others, like Rudolph Tanzi, Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease Harvard believe that even if the drugs fail that science is advancing. Tanzi believes that beta amyloid is "the prime therapeutic target" and that the drugs are bad, not the target. We need better drugs.
Knowing that the day is coming when your loved one -- won't know you-- is the most horrific feeling of them all for an Alzheimer's caregiver. AFR is an Alzheimer's Reading Room companion website.
Saturday, July 14, 2012
Battleground Zero for New Alzheimer's Drug
Subscribe to:
Post Comments (Atom)
Alzheimer's Reading RoomTestimonials
Alzheimer's Reading Room Testimonials Ranked #1 by Healthline in the Best Alzheimer's Blogs - 2012 - 2018 "The Alzheimer’s Re...
-
Alzheimer's disease is a physical illness that causes radical changes in the brain. As healthy brain tissues degenerate persons sufferin...
-
Alzheimer's Reading Room Testimonials Ranked #1 by Healthline in the Best Alzheimer's Blogs - 2012 - 2018 "The Alzheimer’s Re...
No comments:
Post a Comment